6625-45-2

Usage

Uses

Used in Organic Chemistry:
2,6-bis(benzyloxy)benzo-1,4-quinone is used as an oxidation-reduction reagent for its ability to facilitate redox reactions in the synthesis of various organic compounds. Its role in these reactions is essential for the production of a wide range of chemical products.
Used in Pharmaceutical Development:
2,6-bis(benzyloxy)benzo-1,4-quinone is used as a potential building block in the development of pharmaceuticals due to its unique structural properties. Its presence in the synthesis process can contribute to the creation of new drug molecules with potential therapeutic applications.
Used in Agrochemical Development:
2,6-bis(benzyloxy)benzo-1,4-quinone is used in the development of agrochemicals, where its structural properties may contribute to the creation of new compounds with applications in agriculture, such as pesticides or herbicides.
Used in Material Production:
2,6-bis(benzyloxy)benzo-1,4-quinone is used as a versatile building block in the production of new materials, where its structural characteristics can be leveraged to develop innovative materials with unique properties for various applications.

InChI:InChI=1/C20H16O4/c21-17-11-18(23-13-15-7-3-1-4-8-15)20(22)19(12-17)24-14-16-9-5-2-6-10-16/h1-12H,13-14H2

Upstream product

• 55020-64-9 1,2,3-tris-benzyloxybenzene 
• 64-19-7 acetic acid 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 87-66-1 2-hydroxyresorcinol 

Downstream Products

• 42528-82-5 1,2-dibenzyloxy-1,4-hydroquinone-diacetate 
• 42528-81-4 2,6-bis-benzyloxy-benzene-1,4-diol 
• 156481-55-9 1-<2-hydroxy-3,6-dimethoxy-4-(tetrahydropyran-2-yloxy)>phenylethanone 
• 6274-74-4 2,6-dibenzyloxy-1,4-dimethoxybenzene 
• 20032-42-2 2,5-dimethoxyresorcinol 
• 100079-39-8 2',4'-dihydroxy-2,3',6'-trimethoxychalcone 
• 884867-35-0 C₁₈H₁₆O₅ 
• 884867-38-3 C₁₇H₁₃ClO₅ 
• 102273-92-7 7-hydroxy-5,8,2'-trimethoxyflavone 

Relevant academic research and scientific papers

Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity

Wogonin, a natural product isolated from the plant Scutellaria baicalensis, has been shown to be a potent and selective inhibitor of CDK9. With the purpose of investigating the activity and selectivity of this chemical scaffold, several series of wogonin derivatives were prepared and screened for CDK9 inhibition and cellular antiproliferative activity. Among these compounds, the drug-like compound 51 showed potent activity against CDK9 (IC50 = 19.9 nM) and MV4-11 cell growth (IC50 = 20 nM). In addition, compound 51 showed much improved physicochemical properties, such as water solubility, compared with the parent compound wogonin. The follow-up studies showed that the compound 51 is selective toward CDK9-overexpressing cancer cells over normal cells. Preliminary mechanism studies on the anticancer effect indicated that 51 inhibited the proliferation of MV4-11 cells via caspase-dependent apoptosis. In addition, highlighted compound 51 showed significant antitumor activity in mouse acute myeloid leukemia (AML) models without producing apparent toxic effects in vivo, which gave us a new tool for further investigation of CDK9-targeted inhibitor as a potential antitumor drug especially for AML.

Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro

Phenotypic screening of high quality compound library is one of the most effective strategy to obtain novel bioactive compounds. Recently, our group have constructed a Wogonin-scaffold library with substituents diversity and successfully obtained a series

Synthesis, evaluation and quantitative structure–activity relationship (QSAR) analysis of Wogonin derivatives as cytotoxic agents

A novel series of 49 wogonin derivatives were synthesized by introducing group at 7-, 8- or B ring of wogonin. The cytotoxic activities against HepG2, A549 and BCG-823 cancer cell lines were also investigated in vitro. Several of them showed obvious cytotoxic activities and compound 3h possessed the highest potency against HepG2, A549, and BCG-823 with IC50 values of 1.07 μM, 1.74 μM and 0.98 μM, respectively. A quantitative structure-activity relationship (QSAR) study of these synthetic derivatives as well as wogonin indicated that high solubility and low octanol/water partition coefficient are favorable, and excessive electrostatic properties and refractivity are unfavorable for the cytotoxic activities of these wogonin derivatives. These findings and results provide a base for further investigations.

ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS OR PRECURSORS THEREOF

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Total synthesis of seco-lateriflorone

A convergent strategy toward the synthesis of lateriflorone (5) is described. Our approach is based on biosynthetic considerations and draws on a sequence of prenylation, oxygenation and Claisen reactions for the construction of chromenequinone 6, and a tandem Claisen/Diels-Alder reaction cascade for the synthesis of caged tricycle 7. Union of fragments 6 and 7 led to the synthesis of seco-lateriflorone (49).

A khellin-like 7,7'-glycerol-bridged bischromone with anti-anaphylactic activity

The synthesis of the title compound 3 is described. Its performance in Passive Cutaneous Anaphylaxis (PCA) testing was evaluated.